ArticleBiophysics reports
Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification.
Article in Biophysics reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Monomeric C-reactive Protein Exacerbates Neuronal Injury and Enhances Microglial Activation after Global Cerebral Ischemia in Mice.Molecular neurobiology · 2025Article
- Review
- Magnetic Nanoparticles Stabilized by Phosphorylcholine-Containing Polymer for Label-Free C-Reactive Protein Detection.ACS omega · 2025Article
- Circulating Levels of the Proinflammatory Monomeric Isoform of C-Reactive Protein (mCRP) Correlate with Intra-Tumoral mCRP Abundance in Stage II-III Colon Cancer Patients.Journal of inflammation research · 2025Article
- Shear-Sensing by C-Reactive Protein: Linking Aortic Stenosis and Inflammation.Circulation research · 2024Article
- The influences of ApoE isoforms on endothelial adherens junctions and actin cytoskeleton responding to mCRP.Angiogenesis · 2024Article
- Article
- Peripheral apolipoprotein E proteins and their binding to LRP1 antagonize Alzheimer's disease pathogenesis in the brain during peripheral chronic inflammation.Neurobiology of aging · 2023Article
- A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects.Frontiers in immunology · 2023Review
- Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.Cell biochemistry and biophysics · 2022Review
- Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity.Arthritis research & therapy · 2022Article
- Monomeric C-reactive protein level is associated with osteoarthritis.Experimental and therapeutic medicine · 2022Article
- Relevance of lipoproteins, membranes, and extracellular vesicles in understanding C-reactive protein biochemical structure and biological activities.Frontiers in cardiovascular medicine · 2022Review
- Monomeric C-reactive protein induces the cellular pathology of Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Monomeric C reactive protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Article
- Antibody Protection against Long-Term Memory Loss Induced by Monomeric C-Reactive Protein in a Mouse Model of Dementia.Biomedicines · 2021Article
- C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms.Frontiers in immunology · 2021Review
- Connecting secretome to hematopoietic stem cell phenotype shifts in an engineered bone marrow niche.Integrative biology : quantitative biosciences from nano to macro · 2020Article
- How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The precise function of C-reactive protein (CRP) as a regulator of inflammation in health and disease continues to evolve. The true understanding of its role in host defense responses has been hampered by numerous reports of comparable systems with contradictory interpretations of CRP as a stimulator, suppressor, or benign contributor to such processes. These discrepancies may be explained in part by the existence of a naturally occurring CRP isoform, termed modified CRP (i.e., mCRP), that is expressed when CRP subunits are dissociated into monomeric structures. The free mCRP subunit undergoes a non-proteolytic conformational change that has unique solubility, antigenicity, and bioactivity compared to the subunits that remain associated in the native, pentameric CRP molecule (i.e., pCRP). As specific reagents have been developed to identify and quantify mCRP, it has become apparent that this isoform can be formed spontaneously in calcium-free solutions. Furthermore, mCRP can be expressed on perturbed cell membranes with as little as 24-48 h incubation in tissue culture. Because mCRP has the same size as pCRP subunits as evaluated by SDS-PAGE, its presence in a pCRP reagent would not be apparent using this technique to evaluate purity. Finally, because many antibody reagents purported to be specific for "CRP" contains some, or substantial specificity to mCRP, antigen-detection techniques using such reagents may fail to distinguish the specific CRP isoform detected. All these caveats concerning CRP structures and measurements suggest that the aforementioned contradictory studies may reflect to some extent on distinctive bioactivities of mCRP rather than on pCRP. To provide a reliable, abundant supply of mCRP for separate and comparable studies, a recombinant protein was engineered and expressed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.